FM
PCRX icon

Foster & Motley’s Pacira BioSciences PCRX Stock Holding History

Foster & Motley’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Buy
57,817
+817
+1% +$19.3K 0.07% 194
2026
Q1 		$1.29M Buy
57,000
+15,943
+39% +$354K 0.07% 206
2025
Q4 		$1.06M Buy
41,057
+25,984
+172% +$618K 0.06% 221
2025
Q3 		$388K Buy
+15,073
New +$370K 0.02% 319

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Foster & Motley's PCRX Position: Q2 2026 in Review

Foster & Motley increased its Pacira BioSciences (PCRX) stake by 1.4% in Q2 2026, buying an estimated $19.3K and bringing the position to 57,817 shares worth $1.47M. The position accounts for 0.07% of the portfolio, ranked #194.

Foster & Motley first reported a position in PCRX in Q3 2025 and has held it in 4 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Foster & Motley held 57,817 shares of Pacira BioSciences worth $1.47M as of Q2 2026.
  • Foster & Motley bought 817 Pacira BioSciences shares in Q2 2026, an estimated $19.3K.
  • Pacira BioSciences made up 0.07% of Foster & Motley's portfolio in Q2 2026, its #194 holding.
  • Foster & Motley first reported a position in Pacira BioSciences in Q3 2025 and has held it in 4 quarters since.
  • 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Foster & Motley's 13F filing for Q2 2026, filed 7 Aug 2026.